These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37436917)

  • 1. Mucosal α4β7+ Lymphocytes and MAdCAM+ Venules Predict Response to Vedolizumab in Ulcerative Colitis.
    Roosenboom B; Wahab PJ; Smids C; Meijer J; Kemperman LGJM; Groenen MJM; van Lochem EG; Horjus Talabur Horje CS
    Inflamm Bowel Dis; 2024 Jun; 30(6):930-938. PubMed ID: 37436917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline levels of dynamic CD4
    Allner C; Melde M; Becker E; Fuchs F; Mühl L; Klenske E; Müller L; Morgenstern N; Fietkau K; Hirschmann S; Atreya R; Atreya I; Neurath MF; Zundler S
    BMC Gastroenterol; 2020 Apr; 20(1):103. PubMed ID: 32293299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissecting Common and Unique Effects of Anti-α4β7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis.
    Veny M; Garrido-Trigo A; Corraliza AM; Masamunt MC; Bassolas-Molina H; Esteller M; Arroyes M; Tristán E; Fernández-Clotet A; Ordás I; Ricart E; Esteve M; Panés J; Salas A
    J Crohns Colitis; 2021 Mar; 15(3):441-452. PubMed ID: 32926095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal Eosinophilia Is an Independent Predictor of Vedolizumab Efficacy in Inflammatory Bowel Diseases.
    Kim EM; Randall C; Betancourt R; Keene S; Lilly A; Fowler M; Dellon ES; Herfarth HH
    Inflamm Bowel Dis; 2020 Jul; 26(8):1232-1238. PubMed ID: 31633167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vedolizumab Efficacy Is Associated With Decreased Intracolonic Dendritic Cells, Not Memory T Cells.
    Boden EK; Kongala R; Hindmarch DC; Shows DM; Juarez JG; Lord JD
    Inflamm Bowel Dis; 2024 May; 30(5):704-717. PubMed ID: 37837660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis.
    Battat R; Dulai PS; Vande Casteele N; Evans E; Hester KD; Webster E; Jain A; Proudfoot JA; Mairalles A; Neill J; Singh S; Chang JT; Rivera-Nieves J; Sandborn WJ; Boland BS
    Inflamm Bowel Dis; 2019 Jan; 25(2):410-420. PubMed ID: 30295781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.
    Boden EK; Shows DM; Chiorean MV; Lord JD
    Dig Dis Sci; 2018 Sep; 63(9):2419-2429. PubMed ID: 29372476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue Exposure does not Explain Non-Response in Ulcerative Colitis Patients with Adequate Serum Vedolizumab Concentrations.
    Van den Berghe N; Verstockt B; Gils A; Sabino J; Ferrante M; Vermeire S; Declerck P; Thomas D
    J Crohns Colitis; 2021 Jun; 15(6):988-993. PubMed ID: 33245363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of vedolizumab in the treatment of ulcerative colitis.
    Domènech E; Gisbert JP
    Gastroenterol Hepatol; 2016 Dec; 39(10):677-686. PubMed ID: 26948838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease.
    Souza HS; Elia CC; Spencer J; MacDonald TT
    Gut; 1999 Dec; 45(6):856-63. PubMed ID: 10562584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Mucosal PNAd
    Roosenboom B; Lochem EGV; Meijer J; Smids C; Nierkens S; Brand EC; Erp LWV; Kemperman LGJM; Groenen MJM; Horje CSHT; Wahab PJ
    Cells; 2020 Apr; 9(4):. PubMed ID: 32268498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases.
    Coletta M; Paroni M; Alvisi MF; De Luca M; Rulli E; Mazza S; Facciotti F; Lattanzi G; Strati F; Abrignani S; Fantini MC; Vecchi M; Geginat J; Caprioli F
    J Crohns Colitis; 2020 Sep; 14(9):1190-1201. PubMed ID: 32100016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn's Disease and Ulcerative Colitis.
    Noman M; Ferrante M; Bisschops R; De Hertogh G; Van den Broeck K; Rans K; Rutgeerts P; Vermeire S; Van Assche G
    J Crohns Colitis; 2017 Sep; 11(9):1085-1089. PubMed ID: 28369329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo.
    Zundler S; Fischer A; Schillinger D; Binder MT; Atreya R; Rath T; Lopez-Pósadas R; Voskens CJ; Watson A; Atreya I; Neufert C; Neurath MF
    Inflamm Bowel Dis; 2017 Mar; 23(3):379-391. PubMed ID: 28221249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
    Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
    Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC.
    Arijs I; De Hertogh G; Lemmens B; Van Lommel L; de Bruyn M; Vanhove W; Cleynen I; Machiels K; Ferrante M; Schuit F; Van Assche G; Rutgeerts P; Vermeire S
    Gut; 2018 Jan; 67(1):43-52. PubMed ID: 27802155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins?
    D'Amico F; Danese S; Peyrin-Biroulet L
    Expert Opin Biol Ther; 2020 Apr; 20(4):353-361. PubMed ID: 31951748
    [No Abstract]   [Full Text] [Related]  

  • 18. Alterations in MAdCAM1-Positive Mucosal Capillaries and Integrin a4b7-Positive Lymphocytes in Crohn's Disease Treated with Anti-TNFα Biologics.
    Younes M; DuPont AW; Cash BD; Ertan A
    Ann Clin Lab Sci; 2021 Sep; 51(5):678-685. PubMed ID: 34686510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating exosomes express α4β7 integrin and compete with CD4+ T cells for the binding to Vedolizumab.
    Domenis R; Marino M; Cifù A; Scardino G; Curcio F; Fabris M
    PLoS One; 2020; 15(11):e0242342. PubMed ID: 33180848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn's disease.
    Arihiro S; Ohtani H; Suzuki M; Murata M; Ejima C; Oki M; Kinouchi Y; Fukushima K; Sasaki I; Nakamura S; Matsumoto T; Torii A; Toda G; Nagura H
    Pathol Int; 2002; 52(5-6):367-74. PubMed ID: 12100519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.